Table 1

Baseline characteristics of patients receiving anakinra for gouty arthritis.

Baseline characteristics

Clinical characteristics of gouty patients


Number of patients

40

Number of men (%)

32 (80%)

Comorbid conditions (number; %)

HT (27; 68%), CKD 3-5 (22; 55%), CAD (17; 43%), AI (13; 33%), DM (9; 23%), GU (6; 15%), transplant (2 (kidney, heart); 5%), asthma (1; 3%),

Associated therapies (number; %)

LDA (8; 20%), oral anticoagulant (3; 8%),

Age, year, mean ± SD

60.0 ± 13.9

Disease duration, year, mean ± SD

8.7 ± 8.7

Flare duration, number patients (days, mean ± SD)

Acute (<6 weeks)

34 (9.4 ± 8.1)

Subacute (6 to12 weeks)

2 (60.0 ± 1.4)

Chronic (>12 weeks)

4 (130 ± 45.8)

Localization of arthritis, (number; %)

Knees (30; 75%), wrists (22; 55%), ankles (24; 60%), MTP1s (20; 50%), MCPs (12; 30%), elbows (12; 30%), tarsae (6; 15%), shoulders (2; 5%)

Reason for anakinra use

Non-response to conventional therapies, (number; %)

Colchicine (24; 60%), NSAIDs (11; 27.5%), steroids (7; 17.5%)

Adverse events or contraindication to conventional therapies, (number; %)

Colchicine (16; 40%), NSAIDs (29; 72.5%), steroids (9; 22.5%)


AI, alcohol intake; CAD, coronary heart disease; CKD, chronic kidney disease; DM, diabetes mellitus; GU, gastric ulcer; HT, hypertension, LDA, low-dose aspirin; MCPs, metacarpophalangeal joints; MTPs, metatarsophalangeal joints; NSAIDs, non-steroidal anti-inflammatory drugs.

Ottaviani et al. Arthritis Research & Therapy 2013 15:R123   doi:10.1186/ar4303

Open Data